-
Jan 8, 2025 | 
advancingrna.com | AR Welch |Advancing RNA |Kishore Kumar Hotha |Antony Hitchcock
Though the number of CDMOs with mRNA/RNA capabilities is increasing, many of these are better equipped for large-scale, linear mRNA development. Don't miss Advancing RNA Live on January 21st as our panel shares how mRNA and next-gen RNA modality companies need to be evaluating CDMO platforms. Attendance is free thanks to the support of Cytiva.
-
Dec 11, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Tyler Menichiello |C. Schoellhammer
Customized mRNA-LNP SolutionsWith a combined 20-year track record in the manufacturing of lipids, LNP, and mRNA, MilliporeSigma offers customizable mRNA-LNP CDMO services to meet your unique needs from pre-clinical to commercialization. Select integrated services from drug substance to Fill & Finish or individual components tailored to your project. Download the infographic to learn more!During our hour-long conversation, Sagaert and I covered a lot of ground on the current state of the industry.
-
Nov 20, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Peter H. Calcott |Michael Nguyen
Webinar: Early Preclinical Development of mRNA/LNP projects - Setting Up Your Project for a Successful Transition to cGMP ManufacturingJoin us on December 2nd to explore mRNA construct development at Lonza, focusing on cGMP manufacturing, analytical advancements, and testing methods. Gain insights into the transition from research to manufacturing and the technologies shaping mRNA development for future projects. Click here to learn more.
-
Oct 30, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Ben Comer |Tony Duong
It’s impossible to attend an event on the future of RNA therapeutics without hearing about the challenges we’re facing with targeted RNA-LNP delivery. In this final Advancing RNA Live discussion of 2024, we sit down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs. Secure your spot today! Registration is free thanks to the support of Helix Biotech.
-
Oct 2, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Michael Nguyen
As I read through the FDA's draft platform designation guidance and listened to various panel discussions the past few months, a handful of additional observations and considerations came to mind that are important to reiterate for the RNA space, particularly as we advance into therapeutics development. Nutcracker's unique approach to scaling up to clinical manufacturing — which brings unique challenges compared to traditional biologics — relies on microfluidics.
-
Sep 18, 2024 | 
advancingrna.com | AR Welch |Advancing RNA
The success of nucleic acid modalities and LNP delivery systems relies on robust and consistent processes to make and purify the drug substance and then formulate it to ensure successful delivery to the intended target. A range of analytical techniques is necessary to ensure product quality and patient safety. This whitepaper provides a detailed description of assays for sequence identification and LNP composition, two critical quality attributes of mRNA-LNP products. Learn more here.
-
Sep 11, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Michael Nguyen
As I’ve been reminded on a few different occasions, there is a difficult truth we may need to wrap our brains around in certain situations: Just because we can make an mRNA therapy for an indication, doesn’t necessary mean we should — or that the patient population will necessarily want it or be able to access it.
-
Aug 14, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Antony Hitchcock |AGH Bioconsulting
In the first- of this three-part article series, several mRNA execs share their perspectives on the world of partnering in the RNA therapeutics space, assessing first the current state of CDMO partnerships and how they anticipate this critical supportive infrastructure will grow in the years ahead. FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine.
-
May 8, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Takehiro Okumura |Zeb Khan
Designing a Plasmid DNA Downstream Purification ProcessDiscover in our technical article the Downstream Purification in the Plasmid DNA (pDNA) Manufacturing Process. Plasmid DNA (pDNA) is an essential component of, and key technology for production of viral vector, mRNA, and vaccine therapies.
-
Mar 6, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Matthew Pillar |Rebecca Roberts
Here, I offer takeaways from an ARM/ASGCT workshop on one of the most popular topics to gossip about both in and outside the analytical labs: potency assays. In part one of this two-part article, I start by unpacking what I see as the most prominent knowledge gaps and questions underpinning the CGT and RNA sectors' ongoing potency assay challenges.
